|
Nicostatin, rosuvastatin, ezetimibe to debut soon. (Excellent Safety Profiles).
Publication: Internal Medicine News Publication Date: 15-FEB-02 Author: Jancin, Bruce
|
|
COPYRIGHT 2002 International Medical News Group
SNOWMASS, COLO. -- Nicostatin, rosuvastatin, and ezetimibe are three new lipid-lowering drugs that all physicians engaged in coronary disease risk reduction are likely to use in 2002, Dr. Donald B. Hunninghake predicted at a conference sponsored by the American College of Cardiology
Nicostatin (Advicor) received Food and Drug Administration approval in December and is now reaching pharmacy shelves. But physicians may not get deluged with drug detail people promoting the product, since its manufacturer, Kos Pharmaceuticals Inc., is a relatively small company that has...
Read the full article for free courtesy of your local library.
|
Bookmark this article
Print this article
Link to this article
Email this article
Digg It!
Add to del.icio.us
RSS
